Growth Metrics

Biogen (BIIB) Non-Current Deferred Tax Liability (2016 - 2026)

Biogen has reported Non-Current Deferred Tax Liability over the past 18 years, most recently at $483.5 million for Q1 2026.

  • For Q1 2026, Non-Current Deferred Tax Liability rose 262.99% year-over-year to $483.5 million; the TTM value through Mar 2026 reached $483.5 million, up 262.99%, while the annual FY2025 figure was $507.6 million, 166.46% up from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 was $483.5 million at Biogen, down from $507.6 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $882.4 million in Q3 2024 and troughed at $118.3 million in Q2 2025.
  • A 5-year average of $435.5 million and a median of $480.6 million in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 310.42% in 2024 and later tumbled 79.97% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $334.7 million in 2022, then surged by 91.75% to $641.8 million in 2023, then tumbled by 70.32% to $190.5 million in 2024, then skyrocketed by 166.46% to $507.6 million in 2025, then dropped by 4.75% to $483.5 million in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for BIIB at $483.5 million in Q1 2026, $507.6 million in Q4 2025, and $358.1 million in Q3 2025.